A breakthrough treatment offers hope for patients facing one of the deadliest cancers
Category: Health
In a remarkable breakthrough for one of the deadliest forms of cancer, researchers have reported that the experimental drug daraxonrasib significantly extends survival for patients with advanced pancreatic cancer. In a clinical trial involving 500 participants, those treated with daraxonrasib lived a median of 13.2 months, nearly double the 6.7 months seen in patients receiving standard chemotherapy. This development raises hopes for improved treatment options in a field that has seen limited progress for decades.
The clinical trial results for daraxonrasib were unveiled on May 31, 2026, during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The findings were simultaneously published in the New England Journal of Medicine. Dr. Zev Wainberg, co-director of the GI Oncology Program at UCLA, emphasized the significance of the results, stating, "For years we’ve made incremental gains in treating pancreatic cancer. Now, for the first time, we have demonstrated that targeted inhibition of RAS using an oral inhibitor is changing the landscapes of this terrible disease." The trial included patients who had previously undergone chemotherapy but whose cancer had progressed.
Daraxonrasib is a first-in-class oral Ras(On) multi-selective inhibitor that targets the KRAS gene, which is mutated in over 90% of pancreatic cancers. This mutation causes the KRAS protein to remain in an active state, leading to uncontrolled cell growth. The drug works by effectively binding to the mutated protein, acting like a "molecular glue" to inhibit its function. This innovative approach marks a departure from earlier therapies that focused on single mutation subtypes, as daraxonrasib can inhibit multiple KRAS variants.
The implications of this study are immense, particularly considering that pancreatic cancer has the highest mortality rate of all major cancers. According to the American Cancer Society, approximately 68,000 Americans will be diagnosed with pancreatic cancer in 2026, with around 53,000 expected to die from the disease. Historically, treatment options have been limited, with only about 3% of patients diagnosed with metastatic pancreatic cancer surviving five years. Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, noted that these results will change how scientists, clinicians, and patients approach treatment for pancreatic cancer.
The results from the trial indicated that daraxonrasib doubled survival time and improved the quality of life for patients. Participants reported less pain and a greater ability to engage in daily activities compared to those receiving chemotherapy. The drug reduced the risk of death by 60% and halted or reversed tumor progression in nearly a third of patients, compared to just 10% in the chemotherapy group.
Though the findings are promising, daraxonrasib is not without side effects. The most common adverse reactions included rash, nausea, diarrhea, and mouth sores, with 86.3% of patients experiencing a rash, though these side effects were mostly manageable. Only 1.2% of patients discontinued treatment due to adverse events, a stark comparison to 11.2% of those on chemotherapy. As with any new treatment, continued monitoring and research are necessary to fully understand the long-term effects and potential resistance.
The FDA has expedited the review process for daraxonrasib and has allowed expanded access for patients outside of clinical trials. Researchers are also investigating the drug's efficacy in earlier stages of pancreatic cancer treatment and in combination with other therapies. Dr. Wolpin expressed optimism about the future, stating, "Now the floodgates open," indicating that daraxonrasib may pave the way for similar treatments targeting KRAS mutations in other types of cancer.
Experts in the field are hopeful that daraxonrasib could represent a turning point in the treatment of pancreatic cancer. Dr. Rachna Shroff, a pancreatic cancer expert who was not involved in the study, shared her emotional reaction to the results, saying, "Having treated pancreatic cancer for 16 years, I actually started crying in the clinic. This is such an incredibly impactful study for our patients." With the potential to change the standard of care, daraxonrasib offers new hope to patients and families grappling with the challenges of this devastating disease.
As the medical community anticipates the drug's availability, there is a collective sense of urgency to make this treatment accessible to those in need. "More time with those we love most is truly priceless," said Anna Jewell, director of services at Pancreatic Cancer UK. The next steps will involve ensuring that patients can access this promising new treatment as soon as possible.